Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma is a lethal cancer with fewer than 7% of patients surviving past 5 years. T-cell immunity has been linked to the exceptional outcome of the few long-term survivors, yet the relevant antigens remain unknown. Here we use genetic, immunohistochemical and transcriptional immunoprofiling, computational biophysics, and functional assays to identify T-cell antigens in long-term survivors of pancreatic cancer. Using whole-exome sequencing and in silico neoantigen prediction, we found that tumours with both the highest neoantigen number and the most abundant CD8+ T-cell infiltrates, but neither alone, stratified patients with the longest survival. Investigating the specific neoantigen qualities promoting T-cell activation in long-term survivors, we discovered that these individuals were enriched in neoantigen qualities defined by a fitness model, and neoantigens in the tumour antigen MUC16 (also known as CA125). A neoantigen quality fitness model conferring greater immunogenicity to neoantigens with differential presentation and homology to infectious disease-derived peptides identified long-term survivors in two independent datasets, whereas a neoantigen quantity model ascribing greater immunogenicity to increasing neoantigen number alone did not. We detected intratumoural and lasting circulating T-cell reactivity to both high-quality and MUC16 neoantigens in long-term survivors of pancreatic cancer, including clones with specificity to both high-quality neoantigens and predicted cross-reactive microbial epitopes, consistent with neoantigen molecular mimicry. Notably, we observed selective loss of high-quality and MUC16 neoantigenic clones on metastatic progression, suggesting neoantigen immunoediting. Our results identify neoantigens with unique qualities as T-cell targets in pancreatic ductal adenocarcinoma. More broadly, we identify neoantigen quality as a biomarker for immunogenic tumours that may guide the application of immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In rare patients with localized PDAC who are long-term survivors, bacteria can translocate from the intestine into the tumour and control anti-tumour immune activation11,12.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [12]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, the gut microbiota can indirectly increase the immunogenicity of tumor cells by providing tumor cross-antigens to promote the efficacy of ICI [50, 68, 69].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PDAC tumors from long term survivors have high quantity and quality of neoantigens, and stronger infiltration and activation of CD8+ T cells”
From Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes (2019) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These data suggest that microbial host factors, independent of the genomic composition of the tumor, may determine tumor behavior and patient outcomes.”
From Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes (2019) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Significantly, the aggressive progression of PDAC, characterized by immune evasion and therapeutic resistance, is heavily influenced by the TME (Balachandran et al., 2017).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The Ensembl Variant Effect Predictor
McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., Flicek, P., & Cunningham, F. (2016) · Genome Biology · doi:10.1186/s13059-016-0974-4 · Cited by 8,099
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Self-citationWhole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871
Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer
Ino, Y., Yamazaki-Itoh, R., Shimada, K., Iwasaki, M., Kosuge, T., Kanai, Y., & Hiraoka, N. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.32 · Cited by 849
Gros, A., Parkhurst, M. R., Tran, E., Pasetto, A., Robbins, P. F., Ilyas, S., Prickett, T. D., Gartner, J. J., Crystal, J. S., Roberts, I. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4051 · Cited by 829
Cited by
Items 501–600 of 1,001
Hou, W., Yang, B., & Zhu, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102033 · Cited by 27
Heiduk, M., Plesca, I., Glück, J., Müller, L., Digomann, D., Reiche, C., von Renesse, J., Decker, R., Kahlert, C., Sommer, U. J., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.152761 · Cited by 28
Contemplating immunopeptidomes to better predict them
Gfeller, D., Liu, Y., & Racle, J. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2022.101708 · Cited by 32
Ahmed, A., Köhler, S., Klotz, R., Giese, N. A., Hackert, T., Springfeld, C., Zörnig, I., Jäger, D., & Halama, N. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2027148 · Cited by 25
Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases
Sim, W., Lim, W., Hii, L., Leong, C., & Mai, C. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i18.1934 · Cited by 29
James, C. A., Baer, J. M., Zou, C., Panni, U. Y., Knolhoff, B. L., Hogg, G. D., Kingston, N. L., Kang, L., Lander, V. E., Luo, J. R., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0946 · Cited by 26
Huang, J., Gong, C., & Zhou, A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231204854 · Cited by 33
Bradley, S. D., Talukder, A. H., Lai, I. P., Davis, R. K., Alvarez, H., Tiriac, H., Zhang, M., Chiu, Y., Melendez, B., Jackson, K. R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19141-w · Cited by 31
Immunological combination treatment holds the key to improving survival in pancreatic cancer
Sodergren, M. H., Mangal, N., Wasan, H. S., Sadanandam, A., Balachandran, V. P., Jiao, L. R., & Habib, N. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03332-5 · Cited by 28
Self-citationPDAC as an immune evasive disease: can 3D model systems aid to tackle this clinical problem?
Narayanan, S., Vicent, S., & Ponz-Sarvisé, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.787249 · Cited by 24
“In a recent study in long-term survivors of PDAC, the highest number of quality neoantigen load in combination with abundant CD8+ T-cell infiltrates within the tumor correlated with survival (Balachandran et al., 2017).”
BackgroundMinaei, E., Ranson, M., Aghmesheh, M., Sluyter, R., & Vine, K. L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.023 · Cited by 26
An Immunological Glance on Pancreatic Ductal Adenocarcinoma
Melzer, M. K., Arnold, F., Stifter, K., Zengerling, F., Azoitei, N., Seufferlein, T. T. W., Bolenz, C., & Kleger, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093345 · Cited by 29
Predicting in vivo escape dynamics of HIV-1 from a broadly neutralizing antibody
Meijers, M., Vanshylla, K., Gruell, H., Klein, F., & Lässig, M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2104651118 · Cited by 25
Karamitopoulou, E., Andreou, A., de Mortanges, A. P., Tinguely, M., Gloor, B., & Perren, A. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0144 · Cited by 27
Shen, H., Ye, F., Xu, D., Fang, L., Zhang, X., & Zhu, J. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04387-z · Cited by 25
Tomasi, M., Caproni, E., Benedet, M., Zanella, I., Giorgetta, S., Dalsass, M., König, E., Gagliardi, A., Fantappiè, L., Berti, A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.912639 · Cited by 25
Yuan, Y., Fan, J., Liang, D., Wang, S., Luo, X. W., Zhu, Y., Liu, N., Xiang, T., & Zhao, X. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101803 · Cited by 24
Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma
Wattenberg, M. M., Colby, S., Garrido‐Laguna, I., Xue, Y., Chang, R. B., Delman, D., Lee, J., Affolter, K. E., Mulvihill, S. J., Beg, M. S., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.013 · Cited by 24
Altered Binding of Tumor Antigenic Peptides to MHC Class I Affects CD8+ T Cell–Effector Responses
Clancy‐Thompson, E., Devlin, C. A., Tyler, P. M., Servos, M. M., Ali, L. R., Ventre, K. S., Bhuiyan, M. A., Bruck, P. T., Birnbaum, M. E., & Dougan, S. K. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0348 · Cited by 24
Combination treatment of advanced pancreatic cancer using novel vaccine and traditional therapies
Matsui, H., Hazama, S., Shindo, Y., & Nagano, H. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1531707 · Cited by 25
Tumor Control by Cytomegalovirus: A Door Open for Oncolytic Virotherapy?
Herbein, G., & Nehme, Z. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.03.004 · Cited by 24
Jazowiecka-Rakus, J., Hadryś, A., Rahman, M. M., McFadden, G., Fidyk, W., Chmielik, E., Paździor-Heiske, M., Grajek, M., Kozik, V., & Sochanik, A. (2021) · Cancers · doi:10.3390/cancers13061394 · Cited by 26
Shah, A., Chaudhary, S., Lakshmanan, I., Aithal, A., Kisling, S. G., Sorrell, C. L., Marimuthu, S., Gautam, S. K., Rauth, S., Kshirsagar, P., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00423-7 · Cited by 25
Karamitopoulou, E., Wenning, A. S., Acharjee, A., Aeschbacher, P., Marinoni, I., Zlobec, I., Gloor, B., & Perren, A. A. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0368 · Cited by 24
Yang, H., Messina‐Pacheco, J., Corredor, A. L. G., Gregorieff, A., Liu, J., Nehme, A., Najafabadi, H. S., Riazalhosseini, Y., Gao, B., & Gao, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.961457 · Cited by 26
Aziz, H. M., Saida, L., de Koning, W., Stubbs, A., Li, Y., Sideras, K., Palacios, E., Feliú, J., Mendiola, M., van Eijck, C. H. J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.995715 · Cited by 28
PGNneo: A Proteogenomics-Based Neoantigen Prediction Pipeline in Noncoding Regions
Tan, X., Xu, L., Jian, X., Ouyang, J., Hu, B., Yang, X., Wang, T., & Xie, L. (2023) · Cells · doi:10.3390/cells12050782 · Cited by 25
Gouttefangeas, C., Klein, R., & Maia, A. R. R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1212546 · Cited by 28
Li, B., Jing, P., Zheng, G., Pi, C., Zhang, L., Yin, Z., Xu, L., Qiu, J., Gu, H., Qiu, T., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01644-9 · Cited by 25
Leal, A. S., Liu, P., Krieger-Burke, T., Ruggeri, B., & Liby, K. T. (2020) · Cancers · doi:10.3390/cancers13010096 · Cited by 23
Li, R., He, Y., Zhang, H., Wang, J., Liu, X., Liu, H., Wu, H., & Liang, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690056 · Cited by 29
Füchsl, F., & Krackhardt, A. M. (2022) · Cells · doi:10.3390/cells11030410 · Cited by 25
Sarkizova, S., & Hacohen, N. (2017) · Nature · doi:10.1038/d41586-017-07267-9 · Cited by 27
NoisET: Noise Learning and Expansion Detection of T-Cell Receptors
Koraichi, M. B., Touzel, M. P., Mazzolini, A., Mora, T., & Walczak, A. M. (2022) · The Journal of Physical Chemistry A · doi:10.1021/acs.jpca.2c05002 · Cited by 24
Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: Challenges and Early Results
Chick, R. C., Gunderson, A. J., Rahman, S., & Cloyd, J. M. (2023) · Cancers · doi:10.3390/cancers15153967 · Cited by 22
Stem‐like T cells in cancer and autoimmunity
Schnell, A. (2024) · Immunological Reviews · doi:10.1111/imr.13356 · Cited by 22
Niccolai, E., Boem, F., Emmi, G., & Amedei, A. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.03.001 · Cited by 23
Microbiome and cancer immunotherapy
Chilakapati, S. R., Ricciuti, J., & Zsíros, E. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.02.007 · Cited by 23
Relevance of Immune Infiltration and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma Subtypes
Liu, R., Liao, Y.-Z., Zhang, W., & Zhou, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.575264 · Cited by 24
Research Progress of Pancreas-Related Microorganisms and Pancreatic Cancer
Zhang, W., Zhang, K., Zhang, P., Zheng, J., Min, C., & Li, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.604531 · Cited by 26
Barroux, M., Househam, J., Lakatos, E., Ronel, T., Baker, A., Salié, H., Mossner, M., Smith, K., Kimberley, C., Nowinski, S., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00955-w · Cited by 24
Jonckheere, N., Auwercx, J., Bachir, E. H., Coppin, L., Boukrout, N., Vincent, A., Neve, B., Gautier, M., Treviño, V., & SEUNINGEN, I. V. (2020) · Cancers · doi:10.3390/cancers12113309 · Cited by 24
Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance
Ajina, R., Malchiodi, Z. X., Fitzgerald, A. A., Zuo, A., Wang, S., Moussa, M., Cooper, C. J., Shen, Y. L., Johnson, Q. R., Parks, J. M., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0272 · Cited by 25
Mashayekhi, V., Mocellin, O., Fens, M. H. A. M., Krijger, G. C., Brosens, L. A. A., & Oliveira, S. (2021) · Theranostics · doi:10.7150/thno.60350 · Cited by 22
Impact of DNA damage response defects in cancer cells on response to immunotherapy and radiotherapy
Czajkowski, D., Szmyd, R., & Gee, H. E. (2022) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13413 · Cited by 29
Diet-gut microbial interactions influence cancer immunotherapy
Wang, X., & Geng, S.-T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1138362 · Cited by 23
Ma, W., Li, Z.-H., Wu, Z., Liu, F., Wang, J.-K., Shi, Y., Jin, Y., & Li, F. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100920 · Cited by 23
Romero, J. M., Titmuss, E., Wang, Y., Vafiadis, J., Pacis, A., Jang, G. H., Zhang, A. X. W., Golesworthy, B., Lenko, T., Williamson, L., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00428-2 · Cited by 23
Chen, Q., Yin, H., Jiang, Z., He, T., Xie, Y., Mao, W., Han, J., Liu, S., Lou, W., Wu, W., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008694 · Cited by 24
Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel
Brouwer, T. P., Vahrmeijer, A. L., & de Miranda, N. F. C. C. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00587-z · Cited by 23
Precision strategies for cancer treatment by modifying the tumor-related bacteria
Lu, H., Wang, Q., Liu, W., Wen, Z., & Li, Y. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11491-9 · Cited by 22
Pathogens: Our Allies against Cancer?
Buonaguro, L., & Cerullo, V. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.005 · Cited by 21
Ca 125 is an independent prognostic marker in resected pancreatic cancer of the head of the pancreas
Napoli, N., Kauffmann, E. F., Ginesini, M., Lami, L., Lombardo, C., Vistoli, F., Campani, D., & Boggi, U. (2023) · Updates in Surgery · doi:10.1007/s13304-023-01587-4 · Cited by 20
Faghfuri, E. (2023) · Personalized Medicine · doi:10.2217/pme-2023-0054 · Cited by 20
Coschi, C. H., & Juergens, R. A. (2023) · Current Oncology · doi:10.3390/curroncol31010001 · Cited by 26
Immuno-oncology from the perspective of somatic evolution
González, S., Volkova, N. V., Beer, P. A., & Gerstung, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.001 · Cited by 23
Cancer research in the era of immunogenomics
Wolf, Y., & Samuels, Y. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000475 · Cited by 21
Scaling the immune incline in PDAC
Rojas, L. A., & Balachandran, V. P. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00475-9 · Cited by 21
Self-citationLeschiera, E., Lorenzi, T., Shen, S., de Almeida, L. N., & Audebert, C. (2022) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2022.111028 · Cited by 26
Flint, T. R., Jones, J. O., Ferrer, M., Colucci, F., & Janowitz, T. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.03.005 · Cited by 19
Overexpressing PLOD Family Genes Predict Poor Prognosis in Pancreatic Cancer
Zhang, J., Tian, Y. Z., Mo, S. J., & Fu, X. F. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s341332 · Cited by 19
Self-citationIntegrative insights and clinical applications of single-cell sequencing in cancer immunotherapy
Liu, Z., Li, H., Dang, Q., Weng, S., Duo, M., Lv, J., & Han, X. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04608-4 · Cited by 19
The role of extratumoral and intratumoral microorganisms in cancer immunotherapy
Du, Y., Liu, L., Ma, W., Yan, W., Mao, W., Du, Y., Cui, K., Pu, Y., Li, Z., Sansonetti, P. J., et al. (2023) · The Innovation Life · doi:10.59717/j.xinn-life.2023.100016 · Cited by 21
Castro, A., Zanetti, M., & Carter, H. K. (2021) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-092820-112713 · Cited by 20
Neoantigen-specific mRNA/DC vaccines for effective anticancer immunotherapy
Zhang, W., Guan, J., Wang, W., Chen, G., Li, F., & Lu, Z. (2024) · Genes and Immunity · doi:10.1038/s41435-024-00305-3 · Cited by 18
Advances in Vaccine-Based Therapies for Pancreatic Cancer
McMillan, M. T., & Soares, K. C. (2025) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-025-01165-4 · Cited by 19
Intratumoral heterogeneity and immunotherapy resistance: clinical implications
Keenan, B. P., Yadav, M., Ansstas, G., Fabrizio, D. A., Murugesan, K., Montesion, M., Niyogi, D. G., Mellman, I., & Melero, I. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.10.1239 · Cited by 26
Enhanced Immunogenicity of Mitochondrial-Localized Proteins in Cancer Cells
Prota, G., Gileadi, U., Rei, M., Lechuga‐Vieco, A. V., Chen, J., Galiani, S., Bedard, M., Lau, V. W. C., Fanchi, L. F., Artibani, M., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0467 · Cited by 20
Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer
Zhang, X., Xu, Z. Q., Dai, X., Zhang, X., & Wang, X. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1104860 · Cited by 21
Multiomics Empowers Predictive Pancreatic Cancer Immunotherapy
Montagne, J. M., Jaffee, E. M., & Fertig, E. J. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200660 · Cited by 19
Integrating immunopeptidome analysis for the design and development of cancer vaccines
Feola, S., Chiaro, J., & Cerullo, V. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101750 · Cited by 19
Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors
Ai, Q., Li, F., Zou, S., Zhang, Z., Jin, Y., Jiang, L., Chen, H., Deng, X., Peng, C., Mou, N., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1161538 · Cited by 21
Pothuri, V. S., Hogg, G. D., Conant, L., Borcherding, N. C., James, C. A., Mudd, J. L., Williams, G., Seo, Y. D., Hawkins, W. G., Pillarisetty, V. G., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2320411 · Cited by 23
Oyama, K., Nakata, K., Tsutsumi, C., Hayashi, M., Zhang, B., Mochida, Y., Shinkawa, T., Hirotaka, K., Zhong, P., Date, S., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0830 · Cited by 20
Zhang, J., Guan, X., & Zhong, X. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.10.006 · Cited by 26
Self-citationProbing T-cell response by sequence-based probabilistic modeling
Bravi, B., Balachandran, V. P., Greenbaum, B. D., Walczak, A. M., Mora, T., Monasson, R., & Cocco, S. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009297 · Cited by 19
Self-citationCommensal Bifidobacterium Strains Enhance the Efficacy of Neo-Epitope Based Cancer Vaccines
Tomasi, M., Dalsass, M., Beghini, F., Zanella, I., Caproni, E., Fantappiè, L., Gagliardi, A., Irene, C., König, E., Frattini, L. F., et al. (2021) · Vaccines · doi:10.3390/vaccines9111356 · Cited by 21
‘Know thyself’ – host factors influencing cancer response to immune checkpoint inhibitors
Gunjur, A., Manrique-Rincón, A., Klein, O., Behren, A., Lawley, T. D., Welsh, S. J., & Adams, D. J. (2022) · The Journal of Pathology · doi:10.1002/path.5907 · Cited by 20
Zhang, W., Lin, Z., Shi, F., Wang, Q., Kong, Y., Ren, Y., Lyu, J., Sheng, C., Li, Y., Qin, H., et al. (2022) · Cancers · doi:10.3390/cancers14143495 · Cited by 19
Combination immunotherapy for pancreatic cancer: challenges and future considerations
Gössling, G. C. D. L., Zhen, D. B., Pillarisetty, V. G., & Chiorean, E. G. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2120471 · Cited by 19
Enzler, T., & Frankel, T. L. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217662 · Cited by 18
Intratumoral microbiota remodeling of the tumor microenvironment impact solid tumor immunotherapy
Jia, J., Gao, W., Wang, C., Liu, L., Li, Y., Sun, Z., Yang, C., Chen, Y., Yu, H., & Cheng, Y. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08211-w · Cited by 21
Leveraging beneficial microbiome-immune interactions via probiotic use in cancer immunotherapy
Jani, C., Edwards, K., Bhanushali, C. D., Zheng, X. X., Salazar, A. S., Lopes, G. D. L., Jr., & Watson, D. C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1713382 · Cited by 21
Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery
de Sousa, E., Lérias, J. R., López-Beltrán, A., Paraschoudi, G., Condeço, C., Kamiki, J., António, P., Figueiredo, N., Carvalho, C. T., Castillo-Martín, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.592031 · Cited by 19
Intron-Retention Neoantigen Load Predicts Favorable Prognosis in Pancreatic Cancer
Dong, C., Reiter, J. L., Dong, E., Wang, Y., Lee, K. P., Lu, X., & Liu, Y. (2022) · JCO Clinical Cancer Informatics · doi:10.1200/cci.21.00124 · Cited by 23
The microbiota and aging microenvironment in pancreatic cancer: Cell origin and fate
Chen, Z., Wang, Z., Du, Y., Shi, H., & Zhou, W. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188826 · Cited by 17
Analysis of the fecal metagenome in long‐term survivors of pancreas cancer
Kharofa, J. R., Haslam, D. B., Wilkinson, R., Weiss, A., Patel, S. H., Wang, K., Esslinger, H. R., Olowokure, O. O., Sohal, D. P. S., Wilson, G. C., et al. (2023) · Cancer · doi:10.1002/cncr.34748 · Cited by 21
Liu, G., Huang, W., Chen, L., Tayier, N., You, L., Hamza, M., Tian, X., Wang, H., Nie, G., Zhu, M., et al. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101993 · Cited by 17
Plasma cells in human pancreatic ductal adenocarcinoma secrete antibodies against self-antigens
Yao, M., Preall, J. B., Yeh, J. T. ‐., Pappin, D., Cifani, P., Zhao, Y., Shen, S., Moresco, P., He, B., Patel, H., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.172449 · Cited by 25
Self-citationA large-scale study of peptide features defining immunogenicity of cancer neo-epitopes
Wan, Y.-T. R., Koşaloğlu‐Yalçın, Z., Peters, B., & Nielsen, M. (2024) · NAR Cancer · doi:10.1093/narcan/zcae002 · Cited by 19
Genetically engineered membrane-based nanoengagers for immunotherapy of pancreatic cancer
Zhang, H., Li, Y., Kang, H., Lan, J., Hou, L., Chen, Z., Li, F., Liu, Y., Zhao, J., Li, N., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02369-9 · Cited by 17
Self-citationRasool, U., Qian, J., & Aslam, M. Z. (2024) · SAGE Open · doi:10.1177/21582440241256562 · Cited by 19
Zheng, J., & Chen, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1429722 · Cited by 20
Local ablation disrupts immune evasion in pancreatic cancer
Musiu, C., Adamo, A., Caligola, S., Agostini, A., Frusteri, C., Lupo, F., Boschi, F., Busato, A., Poffe, O., Anselmi, C., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217327 · Cited by 18
Domínguez‐Romero, A. N., Martínez‐Cortés, F., Munguía, M. E., Odales, J., Gevorkian, G., & Manoutcharian, K. (2020) · Immunology · doi:10.1111/imm.13233 · Cited by 18
Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival
Bailey, P. J., Zhou, X., An, J., Peccerella, T., Hu, K., Springfeld, C., Büchler, M. W., & Neoptolemos, J. P. (2023) · Function · doi:10.1093/function/zqad011 · Cited by 20
KRAS RENAISSANCE(S) in Tumor Infiltrating B Cells in Pancreatic Cancer
Meng, Q., Valentini, D., Rao, M., & Maeurer, M. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00384 · Cited by 17
Engineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity receptorsPreprint
Johnston, A. C., Alicea, G. M., Lee, C., Patel, P. V., Hanna, E. A., Vaz, E., Forjaz, A., Wan, Z., Nair, P. R., Lim, Y., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.13.571595 · Cited by 19
Febriyanto, T., Muhammad, F., Wijaya, W., Oey, O., & Simadibrata, D. M. (2023) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2023.11.017 · Cited by 20
Liu, X., Song, J., Yuan, M., Zuo, F., Li, H., Tang, L., Wang, X., Wang, X., Xiao, Q., Li, L., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02265-0 · Cited by 21
Metadata
- Authors
- Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., Senbabaoglu, Y., Wells, D. K., Cary, C. I. O., Grbovic-Huezo, O., Attiyeh, M., Medina, B., Zhang, J., Loo, J., Saglimbeni, J., Abu-Akeel, M., Zappasodi, R., Riaz, N., Smoragiewicz, M., Kelley, Z. L., Basturk, O., Gönen, M., Levine, A. J., Allen, P. J., Fearon, D. T., Merad, M., Gnjatic, S., Iacobuzio-Donahue, C. A., Wolchok, J. D., DeMatteo, R. P., Chan, T. A., Greenbaum, B. D., Merghoub, T., & Leach, S. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Parker Institute for Cancer Immunotherapy (US)
- Swim Across America (US)
- University of Cambridge (GB)
- Cold Spring Harbor Laboratory (US)
- Corresponding author
- Balachandran, Vinod P.
- ORCID
- Balachandran, Vinod P.
- Łuksza, Marta
- Zhao, Julia N.
- Makarov, Vladimir
- Herbst, Brian
- Bhanot, Umesh
- Wells, Daniel K.
- Grbovic-Huezo, Olivera
- Attiyeh, Marc
- Medina, Benjamin
- Zappasodi, Roberta
- Riaz, Nadeem
- Smoragiewicz, Martin
- Gönen, Mithat
- Levine, Arnold J.
- Fearon, Douglas T.
- Gnjatic, Sacha
- Wolchok, Jedd D.
- DeMatteo, Ronald P.
- Chan, Timothy A.
- Greenbaum, Benjamin D.
- Merghoub, Taha
- Leach, Steven D.
- Venue
- Nature
- Published
- 2017-11
- Volume
- 551
- Issue
- 7681
- Pages
- 512-516
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC6145146
- OpenAlex
- W2767699537
- Cited by
- 1,191
- References
- 28
- Citations by year
- 2026: 89 · 2025: 114 · 2024: 119 · 2023: 178 · 2022: 169 · 2021: 153 · 2020: 135 · 2019: 132 · 2018: 94 · 2017: 6
- FWCI
- 44.60
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (submittedVersion)
- Funders
- Pancreatic Cancer UK (RIF2015_A06_Jamieson)
- Wellcome Trust (103721/Z/14/Z)
- Cancer Research UK (23526, 17263, 15678)
- Academy of Medical Sciences (AMS-SGCL9-Jamieson)
- Agence Nationale de la Recherche (ANR-18-CE14-0005)
- National Institutes of Health
- National Cancer Institute (P01CA087497, P30-CA-08748, R01CA190400, P30CA008748, T32CA009501, K12CA184746)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK097087)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- pancreatic ductal adenocarcinoma, long-term survival, neoantigens, CA125, CD8+ T cells, T cell immunity, immunogenicity, mutational burden, immune evasion
- MeSH terms
- Cancer Survivors, Exome Sequencing, Adenocarcinoma, Antigens, Neoplasm, Bacterial Proteins, Computer Simulation, Cross Reactions, Humans, Immunotherapy, Membrane Proteins, Pancreatic Neoplasms, Prognosis, T-Lymphocytes, Cytotoxic, Survival Analysis, CA-125 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.